Literature DB >> 16649722

Aspirin resistance, an emerging, often overlooked, factor in the management of patients with coronary artery disease.

Amgad N Makaryus1.   

Abstract

Aspirin is the most widely used medication in patients with cardiovascular disease. It has had a greater effect on patients with cardiovascular disease than any other drug. With the importance of aspirin now known for decades, it is recently becoming clearer that some patients do not derive as great a benefit from this "wonder drug" secondary to their resistance to its effects. Aspirin resistance, its prevalence, its identification, and how to overcome or avert it with other medications then becomes a central topic of discussion as important, if not more so, than the importance of aspirin itself as a cornerstone in the treatment of patients with cardiovascular disease. This review explores the current understanding of the mechanism of aspirin resistance with regard to its prevalence and the magnitude of its clinical significance. It also examines the therapeutic implications of a diagnosis of aspirin resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16649722      PMCID: PMC6654371     

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  32 in total

1.  Aspirin resistance after coronary artery bypass grafting.

Authors:  N Zimmermann; P Kienzle; A A Weber; J Winter; E Gams; K Schrör; T Hohlfeld
Journal:  J Thorac Cardiovasc Surg       Date:  2001-05       Impact factor: 5.209

2.  Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?

Authors:  Marc K Halushka; Perry V Halushka
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

3.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease.

Authors:  P A Gum; K Kottke-Marchant; E D Poggio; H Gurm; P A Welsh; L Brooks; S K Sapp; E J Topol
Journal:  Am J Cardiol       Date:  2001-08-01       Impact factor: 2.778

4.  Towards a definition of aspirin resistance: a typological approach.

Authors:  Artur-Aron Weber; Boris Przytulski; Andrea Schanz; Thomas Hohlfeld; Karsten Schrör
Journal:  Platelets       Date:  2002-02       Impact factor: 3.862

5.  Higher prevalence of GPIIIa PlA2 polymorphism in siblings of patients with premature coronary heart disease.

Authors:  P J Goldschmidt-Clermont; L D Coleman; Y M Pham; G E Cooke; W S Shear; E J Weiss; B G Kral; T F Moy; R M Yook; R S Blumenthal; D M Becker; L C Becker; P F Bray
Journal:  Arch Pathol Lab Med       Date:  1999-12       Impact factor: 5.534

6.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

7.  PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement.

Authors:  A Kastrati; W Koch; M Gawaz; J Mehilli; C Böttiger; K Schömig; N von Beckerath; A Schömig
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

8.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

9.  Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina.

Authors:  F Cipollone; G Ciabattoni; P Patrignani; M Pasquale; D Di Gregorio; T Bucciarelli; G Davì; F Cuccurullo; C Patrono
Journal:  Circulation       Date:  2000-08-29       Impact factor: 29.690

10.  Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.

Authors:  John W Eikelboom; Jack Hirsh; Jeffrey I Weitz; Marilyn Johnston; Qilong Yi; Salim Yusuf
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.